REVB
Revelation Biosciences, Inc.0.9825
+0.0225+2.34%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
5.82MP/E (TTM)
0.01Basic EPS (TTM)
81.25Dividend Yield
0%Recent Filings
8-K
Stockholders approve warrant shares
Revelation Biosciences stockholders approved issuing common shares upon exercise of Class J Warrants from January 26, 2026, sidestepping Nasdaq's 20% Exchange Cap rule at the March 18 special meeting. With 4,033,345 for and just 104,162 against, warrants now expire March 18, 2031. Approval unlocks potential dilution.
10-K
FY2025 results
Revelation Biosciences, a clinical-stage biotech, reported FY2025 ended December 31, 2025 with no revenue as it advances Gemini for AKI and CKD, but its audited financials carry a going concern qualification since current cash won't sustain operations past one year without fresh funding. Multiple reverse stock splits in 2024-2026, including 1-for-4 on January 28, 2026, slashed shares to 3.7 million outstanding by February 2026 while market value of non-affiliate equity hit just $3.4 million as of June 30, 2025. No quarterly financials or profitability metrics disclosed in the 10-K. Plans call for Phase 2/3 AKI trial infrastructure in 2026 after FDA alignment. Cash burn demands dilution. Stock stays volatile.
8-K
Q4 loss narrows, cash extends runway
Revelation Biosciences reported Q4 2025 net loss of $2.5M, or $(1.65) per share, improved from $1.7M or $(59.76) in 2024, with full-year loss narrowing to $8.9M from $15.0M. Cash climbed to $10.7M from $6.5M, funding operations into Q1 2027. Positive PRIME study results and FDA-aligned Phase 2/3 for Gemini in AKI advanced the pipeline.
8-K
Warrant inducement yields $7.3M
Revelation Biosciences induced two holders to exercise 8,544,999 pre-split Class I warrants at $0.86 per share, netting ~$7.3M gross proceeds before 8% Roth fees. In exchange, it issued 17,089,998 pre-split Class J warrants—exercisable post-stockholder approval at the same price for five years—to fuel clinical trials and working capital. New warrants await resale registration. Cash in; dilution pending.
8-K
FDA clears Gemini AKI pathway
Revelation Biosciences secured FDA agreement on January 21, 2026, for a single adaptive Phase 2/3 study of Gemini in AKI, using a composite endpoint of death or dialysis need in ~300 patients—enough for NDA submission. This clears a fast path to approval for the first potential AKI therapy beyond dialysis. Infrastructure builds through 2026. Risks shadow clinical execution.
IPO
Employees
Sector
Industry
ENVB
Enveric Biosciences, Inc.
5.24-0.12
IMA
ImageneBio, Inc.
6.25+0.08
INBX
Inhibrx Biosciences, Inc.
81.57+5.36
KALA
KALA BIO, Inc.
0.56-0.05
NUVB
Nuvation Bio Inc.
8.66+0.15
RENB
Lunai Bioworks Inc.
1.42+0.00
RNXT
RenovoRx, Inc.
0.84-0.10
RVPH
Reviva Pharmaceuticals Holdings
0.64+0.01
RVRC
REVIUM RECOVERY INC
0.52+0.00
TRML
Tourmaline Bio, Inc.
47.98+47.98